Skip to main content
Clinical Trials/NCT01925365
NCT01925365CompletedNot Applicable

Hypocholesterolaemic and Prebiotic Effects of a Whole-grain Oat-based Breakfast Cereal in a Cardio-metabolic 'at Risk' Population

University of Reading1 site in 1 country30 target enrollmentStarted: May 1, 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
Changes in faecal bacteria population

Study Overview

Brief Summary

Intake of whole grain cereals has been associated with reducing the risk of hyperlipidaemia and heart disease, however the mechanisms by which oats or oat fractions exert this effect is not totally clear. Furthermore, several large epidemiological studies and a number of recent meta-analyses of nutritional interventions have reported a positive association between increased whole grain intake and reduced risk of developing a range of chronic diseases. Recognising the important role of the gut microbiota in metabolism and metabolic disease risk, we examined the impact of whole grain oats on the human gut microbiota and cardio-metabolic risk factors.

The main aims of this human study is to determine the effectiveness of a low GI whole grain oats breakfast cereal compared to a high GI, refined breakfast cereal to beneficially modulate gut microbiota and its metabolic output, plasma lipids, gut satiety hormones and inflammation markers in an at risk of cardio-metabolic disease population

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Prevention
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
23 Years to 64 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Men and Women (age range 23-64 y)
  • •BMI of 18-30kg/m2
  • •Fasting glucose concentration >5.5 but <7.5mmol/L
  • •Total cholesterol >5.2 but <7.8mmol/L

Exclusion Criteria

  • •medical history of heart disease, diabetes mellitus, cancer, pancreatitis or renal disease
  • •use of lipid lowering drugs, systemic corticosteroids or drugs for regulating hemostasis
  • •exposure to any investigational agent <42 d before the study
  • •presence of gastrointestinal disorder or use of a drug likely to alter gastrointestinal motility or nutrient absorption
  • •history of substance misuse or alcoholism
  • •current pregnancy, planned pregnancy, or given birth in the past 12 months
  • •antibiotic treatment 6 weeks previous to study start date
  • •allergy or intolerance to intervention breakfast cereals components

Arms & Interventions

Wholegrain cereal oats

Experimental

Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.

Intervention: wholegrain cereals oats (WGO) (Dietary Supplement)

Non wholegrain cereals

Placebo Comparator

Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.

Intervention: Non wholegrain cereals (Dietary Supplement)

Outcomes

Primary Outcomes

Changes in faecal bacteria population

Time Frame: Changes in faecal bacteria populations upon consumption of the test and control cereals . Faecal samples were collected and analysed at 0, 42, 56, 112, 140 days

Secondary Outcomes

  • Faecal short chain fatty acids(High-performance liquid chromatography (HPLC) was performed to determine faecal SCFA concentration. Faecal samples were collected and analysed at 0, 42, 56, 112, 140 days)
  • Changes in plasma lipids(Fasted plasma samples were analysed for determination of triacylglycerol (TAG), total cholesterol (TC), HDL-cholesterol, LDL-cholesterol. Blood plasma samples were collected and analysed at 0, 42, 56, 112, 140 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Julie Lovegrove

Professor

University of Reading

Study Sites (1)

Loading locations...

Similar Trials